

# Exclusive speaker interview with Yaniv Erlich, CEO, Eleven Therapeutics released ahead of the RNA Therapeutics Conference

*SAE Media Group reports: Just 2 weeks away for the anticipated RNA Therapeutics conference in London.*

LONDON, UK, January 22, 2023 /EINPresswire.com/ -- With just two weeks remaining until SAE Media Group's 14th Annual RNA Therapeutics Conference convenes on 8 – 9 February 2023, interested attendees are being encouraged to register to secure their place.



Featuring over 20 engaging presentations from senior experts, including 3 spotlight sessions on leading advances of RNA developments and 2 cutting edge panel discussions.

Interested parties can register for attendance at: <http://www.therapeutics-rna.com/PR4ein>

Ahead of the 14th Annual RNA Therapeutics conference, SAE Media Group caught up with

Dr. Yaniv Erlich, CEO, Eleven Therapeutics, for an exclusive speaker interview to discuss the

key challenges and developments within the RNA Therapeutics field. See below an excerpt of the speaker interview:

The RNA Therapeutics market has continued to mature over recent years, what key differences have you noticed in the last year regarding significant developments?

RNA therapeutics has changed from a fringe domain to be mainstream, almost a household term, thanks for the covid19 vaccines

What do you see as the greatest challenge for you to overcome personally in the RNA field at the moment?

Two challenges: (a) getting therapeutics with a long duration of effect (b) targeted delivery

What are your thoughts on [mRNA](#) regulatory successes and AI as key drivers, how do they impact the industry and how are they currently impacting your role?

We are highly excited about the opportunities that are ushered in by AI to understand the structure activity relationship of chemical modifications and genetic elements to RNA molecules and changing their activity levels.

Dr. Yaniv Erlich will be presenting on day one of the RNA Therapeutics conference on “Optimizing RNAi Applications Through Novel AI Technologies” which covers:

- Utilising massively parallel combinatorial searches and AI algorithms to unleash the full power of RNAi
  - Reviewing the structure-activity relationship (SAR) of RNAi molecules to enhance drug safety and efficacy
  - Developing the next generation of RNAi therapeutics to silence the disease-causing genes
- Read the full speaker interview at: [www.therapeutics-rna.com/PR4](http://www.therapeutics-rna.com/PR4) and register for the two-day conference.

Sponsors and Exhibitors: ABZU, eTheRNA, Euroapi, Polypeptide Group, Roche Diagnostics, Sartorius BIA Separations, Symbiosis [Pharmaceutical](#) Services

For sponsorship enquiries contact Andrew Gibbons at [andrew.gibbons@saemediagroup.com](mailto:andrew.gibbons@saemediagroup.com) or +44 (0) 20 7827 6156

For media enquiries contact Marketing, Lamprini Balasi at [lamprini.balasi@saemediagroup.com](mailto:lamprini.balasi@saemediagroup.com) or +44 (0) 20 7827 6732

14th Annual RNA Therapeutics

8 – 9 February 2023

London, UK

[#RNATx2023](#)

[www.therapeutics-rna.com/PR4ein](http://www.therapeutics-rna.com/PR4ein)

----- END -----

About SAE Media Group Conferences:

SAE Media Group Conferences connects global communities with focused networking conferences. We provide our customers with solutions through industry knowledge and collaboration that enables our attendees to return to their organisations better equipped to overcome their key business challenges. Our key events focus on Defence and Aerospace, Pharmaceutical and Medical. Each year we bring together over 5,000 senior business professionals at our conferences. <http://www.smgconferences.com>

SAE Media Group (SMG), a subsidiary of SAE International, reports the latest technology breakthroughs and design innovations to a global audience of nearly 1,000,000 engineers, researchers, and business managers. SMG provides critical information these professionals need to develop new and improved products and services.

Lamprini Balasi  
SAE Media Group  
+442078276162 ext.  
[email us here](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/612769111>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2023 Newsmatics Inc. All Right Reserved.